ForSight Robotics, a pioneer in ophthalmic (eye) robotic surgery, and a developer of a robotics-based surgical platform for vision-saving procedures has raised a $55 million Series A round to advance its surgical robot platform ORYOM, which the company said can perform fully robotic cataract surgeries.
ForSight said its flagship robotic platform will increase accessibility to ophthalmic surgery procedures worldwide and ultimately, transform the future of eye surgery.
The Adani Group led the funding round alongside existing investors Eclipse Ventures and Mithril Capital. A number of new investors, including Provenio Capital, Precision Capital, Reiya Ventures, the Ljungstrom family office, and other prominent private investors also joined the round.
ForSight has advanced its technological capabilities and doubled in size following an initial $10 million mega-seed round last year.
The funding will be used to accelerate the development of the ForSight’s ORYOM platform in clinical trials. The company is working on other preventable ophthalmic diseases that can benefit from the accuracy of a robotics platform and advanced visualization such as retinal diseases and glaucoma among others.
The ORYOM platform has already been used successfully in multiple cataract procedures on an animal eye model by a number of ophthalmic surgeons. ORYOM – which means “daylight” in Hebrew – leverages cutting-edge technologies in microsurgical robotics, computer visualization, and machine learning. The platform will automate the complex subtleties of ophthalmic surgery to treat the diseases underlying preventable blindness with an intuitive platform. It will raise the bar for high-quality procedures with superhuman submillimeter accuracy – 10 times more accurate than the human hand – delivering ultimate consistency, for extremely safe surgeries with optimal refractive outcomes.
ForSight aims to bridge the worldwide gap in the accessibility to eye surgery, and help over one billion people who suffer from preventable vision impairment and eye diseases. ForSight’s first procedure is cataract surgery, the most common surgical procedure with approximately 28M procedures worldwide per year.
“We are pleased to be able to advance our technology with this investment to bring robotics into the world of ophthalmic surgery to help millions of patients who have to wait unnecessarily for procedures while their eyesight deteriorates,” says ForSight CEO and Co-Founder Dr. Daniel Glozman. “Our goal is to democratize this highly sophisticated procedure, enabling patients around the world to easily access the treatment that can restore their vision.”